FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma

NCT03528876 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

36

Enrollment

OTHER

Sponsor class

Stopped Combination of chemotherapy and Immunotherapy is a new Standard of care

Conditions

Metastatic Gastro-esophageal Adenocarcinoma

Interventions

DRUG: FOLFOX and FOLFIRI

Sponsor

University of Saskatchewan